ES2437640T3 - Combinaciones de un agente anticanceroso y un derivado del colestanol - Google Patents

Combinaciones de un agente anticanceroso y un derivado del colestanol Download PDF

Info

Publication number
ES2437640T3
ES2437640T3 ES09718009.5T ES09718009T ES2437640T3 ES 2437640 T3 ES2437640 T3 ES 2437640T3 ES 09718009 T ES09718009 T ES 09718009T ES 2437640 T3 ES2437640 T3 ES 2437640T3
Authority
ES
Spain
Prior art keywords
cancer
agent
cholestanol
cddp
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09718009.5T
Other languages
English (en)
Spanish (es)
Inventor
Shin Yazawa
Toyo Nishimura
Takayuki Asao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gunma University NUC
Otsuka Pharmaceutical Co Ltd
Original Assignee
Gunma University NUC
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gunma University NUC, Otsuka Pharmaceutical Co Ltd filed Critical Gunma University NUC
Application granted granted Critical
Publication of ES2437640T3 publication Critical patent/ES2437640T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J17/005—Glycosides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES09718009.5T 2008-03-05 2009-03-04 Combinaciones de un agente anticanceroso y un derivado del colestanol Active ES2437640T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008055284 2008-03-05
JP2008055284 2008-03-05
PCT/JP2009/000985 WO2009110235A1 (ja) 2008-03-05 2009-03-04 コレスタノール誘導体の併用用途

Publications (1)

Publication Number Publication Date
ES2437640T3 true ES2437640T3 (es) 2014-01-13

Family

ID=41055800

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09718009.5T Active ES2437640T3 (es) 2008-03-05 2009-03-04 Combinaciones de un agente anticanceroso y un derivado del colestanol

Country Status (27)

Country Link
US (6) US8088744B2 (hr)
EP (1) EP2251014B8 (hr)
JP (1) JP5336466B2 (hr)
KR (1) KR20100120674A (hr)
CN (2) CN101678037B (hr)
AR (1) AR070857A1 (hr)
AU (1) AU2009220699C1 (hr)
BR (2) BRPI0908756A2 (hr)
CA (1) CA2717135A1 (hr)
CO (2) CO6311080A2 (hr)
CY (1) CY1115217T1 (hr)
DK (1) DK2251014T3 (hr)
ES (1) ES2437640T3 (hr)
HK (1) HK1145455A1 (hr)
HR (2) HRP20140154T1 (hr)
IL (1) IL207874A (hr)
MX (1) MX2010009794A (hr)
NZ (2) NZ587729A (hr)
PL (1) PL2251014T3 (hr)
PT (1) PT2251014E (hr)
RU (1) RU2492865C2 (hr)
SG (2) SG188805A1 (hr)
SI (1) SI2251014T1 (hr)
TW (1) TWI492759B (hr)
UA (2) UA101831C2 (hr)
WO (1) WO2009110235A1 (hr)
ZA (1) ZA201006228B (hr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ589967A (en) * 2004-01-14 2012-07-27 Gilead Sciences Inc Lipid-based dispersions useful for drug delivery
JP5480241B2 (ja) * 2009-03-04 2014-04-23 大塚製薬株式会社 コレスタノール誘導体の併用用途
PT2404608E (pt) * 2009-03-04 2015-07-21 Otsuka Pharma Co Ltd Derivado de colestanol para utilização combinada
WO2013179310A1 (en) * 2012-05-31 2013-12-05 Mylan Laboratories Limited Stable aqueous compositions of pemetrexed
WO2024018412A1 (en) * 2022-07-20 2024-01-25 University Of The Witwatersrand, Johannesburg 2-hydroxypropyl-beta-cyclodextrin as a cancer therapy neoadjuvant or adjuvant

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5782310A (en) 1980-11-11 1982-05-22 Tanabe Seiyaku Co Ltd Production of liposome preparation
JPS6012127A (ja) 1983-06-30 1985-01-22 Dai Ichi Seiyaku Co Ltd リポソ−ムの製法
JPS6058915A (ja) 1983-09-12 1985-04-05 Fujisawa Pharmaceut Co Ltd 薬物含有脂質小胞体製剤
JPH0610131B2 (ja) 1987-10-30 1994-02-09 テルモ株式会社 リポソームの製法
JPH01167218A (ja) 1987-12-22 1989-06-30 Sumitomo Electric Ind Ltd 超電導薄膜の作製方法
JPH082780B2 (ja) 1990-05-28 1996-01-17 テルモ株式会社 リポソームの製法
JP3831958B2 (ja) 1995-09-20 2006-10-11 日本油脂株式会社 リポソーム用混合脂質及びリポソーム分散液
JP4105258B2 (ja) * 1997-08-19 2008-06-25 大塚製薬株式会社 コレスタノール化合物及びこれを含有する医薬
JP4351314B2 (ja) 1998-12-24 2009-10-28 大塚製薬株式会社 コレスタノール化合物及びこれを含有する医薬
EE200200565A (et) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
CN1822844B (zh) * 2003-07-17 2012-05-09 大塚制药株式会社 含配糖物的脂质体
NZ547252A (en) * 2003-12-08 2008-09-26 Univ Arizona Synergistic anti-cancer compositions
RS50613B (sr) * 2004-05-28 2010-06-30 4Sc Ag Tetrahidropiridotiofeni
TWI373473B (en) * 2005-09-02 2012-10-01 Otsuka Pharma Co Ltd Anticancer agent

Also Published As

Publication number Publication date
UA101884C2 (uk) 2013-05-13
CA2717135A1 (en) 2009-09-11
NZ587729A (en) 2012-03-30
CN101969961B (zh) 2013-01-16
US8088744B2 (en) 2012-01-03
PT2251014E (pt) 2014-02-14
US20120009251A1 (en) 2012-01-12
TW200940097A (en) 2009-10-01
AU2009220699B2 (en) 2013-06-20
HRP20150418T1 (hr) 2015-05-08
HK1145455A1 (en) 2011-04-21
RU2492865C2 (ru) 2013-09-20
SG10201400171PA (en) 2014-06-27
HRP20140154T1 (hr) 2014-03-14
NZ595615A (en) 2013-06-28
EP2251014A1 (en) 2010-11-17
BRPI0908756A2 (pt) 2015-07-21
CO6361931A2 (es) 2012-01-20
AU2009220699C1 (en) 2014-01-16
EP2251014B8 (en) 2014-01-08
DK2251014T3 (da) 2013-12-02
US20140178464A1 (en) 2014-06-26
EP2251014A4 (en) 2012-05-23
US20130101679A1 (en) 2013-04-25
MX2010009794A (es) 2010-12-21
CO6311080A2 (es) 2011-08-22
SI2251014T1 (sl) 2014-02-28
IL207874A0 (en) 2010-12-30
CY1115217T1 (el) 2017-01-04
UA101831C2 (uk) 2013-05-13
AU2009220699A1 (en) 2009-09-11
WO2009110235A1 (ja) 2009-09-11
EP2251014B1 (en) 2013-11-20
IL207874A (en) 2014-05-28
BRPI0924525A2 (pt) 2016-03-01
US20150374730A1 (en) 2015-12-31
CN101678037A (zh) 2010-03-24
PL2251014T3 (pl) 2014-04-30
RU2010140611A (ru) 2012-04-10
SG188805A1 (en) 2013-04-30
ZA201006228B (en) 2011-11-30
JP5336466B2 (ja) 2013-11-06
US20100062053A1 (en) 2010-03-11
KR20100120674A (ko) 2010-11-16
TWI492759B (zh) 2015-07-21
CN101969961A (zh) 2011-02-09
AR070857A1 (es) 2010-05-12
CN101678037B (zh) 2012-07-25
US20120015025A1 (en) 2012-01-19
JPWO2009110235A1 (ja) 2011-07-14

Similar Documents

Publication Publication Date Title
EP2786754B1 (en) Combination therapy with a mitotic inhibitor
ES2437640T3 (es) Combinaciones de un agente anticanceroso y un derivado del colestanol
ES2441593T3 (es) Composiciones para estimular la actividad de terapias anticáncer
WO2010143986A1 (en) Combined therapy of colorectal carcinoma
ES2534800T3 (es) Derivado de colestanol para uso combinado
ES2280972T3 (es) Preparaciones farmaceuticas combinadas que contienen glutaminasa y antraciclinas o compuestos de platino antineoplasicos para la terapia del cancer.
JP5480241B2 (ja) コレスタノール誘導体の併用用途